Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01344837 · ClinicalTrials.gov registry record
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer
A clinical trial of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 360
- Enrollment target
- 1
- Study location
NCT01344837 is a study of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 360 participants, above the 272-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01344837, a study of Endometrial Serous Adenocarcinoma and Stage I Uterine Corpus Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
Conditions Studied
Interventions
- OTHER Medical Chart Review
- OTHER Diagnostic Laboratory Biomarker Analysis
- OTHER Study of Socioeconomic and Demographic Variables
- OTHER Immunohistochemistry Staining Method
- GENETIC Microarray Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2010-01 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01344837
The ClinicalTrials.gov registry entry for NCT01344837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 272-participant average among 12 other Endometrial Serous Adenocarcinoma trials with a reported enrollment target (32% higher). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Endometrial Serous Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Medical Chart Review is the first listed.
NCT01344837 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01344837 about?
NCT01344837 is a clinical study titled "Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer". This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
What is the current status of trial NCT01344837?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2010-01. Estimated completion is 2018-01.
What conditions does trial NCT01344837 study?
This clinical trial studies the following conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer.
What interventions are being tested in trial NCT01344837?
The interventions under investigation include: Medical Chart Review (OTHER), Diagnostic Laboratory Biomarker Analysis (OTHER), Study of Socioeconomic and Demographic Variables (OTHER), Immunohistochemistry Staining Method (OTHER), Microarray Analysis (GENETIC).
Who is sponsoring clinical trial NCT01344837?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01344837 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
RECRUITING · Phase 3
-
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
RECRUITING
-
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
ACTIVE NOT RECRUITING · NA
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Endometrial Serous Adenocarcinoma
All registered trials for this condition
Stage I Uterine Corpus Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.